Immucell Corp (ICCC)

Price$9.67

Value ScoreC

Growth ScoreB

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)106.68%

Price vs S&P 500 (4W)12.32%

VGM Score61.60

Market Capitalization$92.64M

All Metrics

P/CF (Annual)37.43x

Book Value / Share (Quarterly)$3.22

P/TBV (Annual)2.06x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)14.18%

Cash Flow / Share (Quarterly)$0.37

Price vs S&P 500 (YTD)55.57%

Gross Margin (TTM)42.59%

Net Profit Margin (TTM)-1.82%

EPS (TTM)$-0.06

10-Day Avg Trading Volume0.05M

EPS Excl Extra (TTM)$-0.06

Revenue Growth (5Y)12.50%

EPS (Annual)$-0.12

ROI (Annual)-2.88%

Gross Margin (Annual)41.40%

Net Profit Margin (5Y Avg)-11.76%

Cash / Share (Quarterly)$0.75

P/E Basic Excl Extra (TTM)25.81x

Revenue Growth QoQ (YoY)28.39%

ROA (Last FY)-2.45%

Revenue Growth TTM (YoY)9.64%

EBITD / Share (TTM)$0.27

ROE (5Y Avg)-8.65%

Operating Margin (TTM)-0.55%

Cash Flow / Share (Annual)$0.14

P/B Ratio3.18x

P/B Ratio (Quarterly)1.97x

Net Income / Employee (Annual)$-14,200

EV / Revenue (TTM)3.16x

Net Interest Coverage (TTM)-2.07x

ROA (TTM)-1.22%

EPS Growth QoQ (YoY)33.21%

EV / EBITDA (TTM)39.36x

EPS Incl Extra (Annual)$-0.12

Current Ratio (Annual)4.26x

Quick Ratio (Quarterly)2.44x

3-Month Avg Trading Volume0.02M

52-Week Price Return63.58%

EV / Free Cash Flow (Annual)77.18x

P/E Incl Extra (TTM)25.81x

Revenue / Employee (TTM)$410,100

Tangible BV / Share (Quarterly)$2.99

P/S Ratio (Annual)3.35x

Asset Turnover (Annual)0.65x

52-Week High$10.75

Operating Margin (5Y Avg)-10.04%

EPS Excl Extra (Annual)$-0.12

CapEx CAGR (5Y)-21.02%

Tangible BV CAGR (5Y)-0.80%

26-Week Price Return122.61%

Quick Ratio (Annual)1.82x

13-Week Price Return56.34%

Total Debt / Equity (Annual)0.34x

Current Ratio (Quarterly)4.82x

Enterprise Value$94.53M

Revenue / Share Growth (5Y)7.56%

Asset Turnover (TTM)0.67x

Book Value / Share Growth (5Y)-5.24%

Revenue / Employee (Annual)$378,700

Inventory Turnover (Annual)1.98x

Pretax Margin (Annual)-3.72%

Cash / Share (Annual)$0.42

3-Month Return Std Dev55.64%

Gross Margin (5Y Avg)35.95%

Net Income / Employee (TTM)$-7,500

EBITDA CAGR (5Y)3.43%

EBITDA Interim CAGR (5Y)59.76%

ROE (Last FY)-3.84%

Net Interest Coverage (Annual)-0.75x

EPS Basic Excl Extra (Annual)$-0.12

P/FCF (TTM)17.98x

Receivables Turnover (TTM)9.91x

EV / Free Cash Flow (TTM)28.00x

Total Debt / Equity (Quarterly)0.30x

EPS Incl Extra (TTM)$-0.06

Receivables Turnover (Annual)7.69x

ROI (TTM)-1.43%

P/S Ratio (TTM)3.09x

Pretax Margin (5Y Avg)-11.72%

Revenue / Share (Annual)$3.06

Tangible BV / Share (Annual)$2.99

Price vs S&P 500 (52W)35.37%

P/E Ratio (TTM)25.81x

Year-to-Date Return66.50%

5-Day Price Return1.19%

EPS Normalized (Annual)$-0.12

ROA (5Y Avg)-5.23%

Net Profit Margin (Annual)-3.76%

Month-to-Date Return21.04%

Cash Flow / Share (TTM)$-0.47

EBITD / Share (Annual)$0.23

Operating Margin (Annual)-2.14%

LT Debt / Equity (Annual)0.28x

P/CF (TTM)20.70x

ROI (5Y Avg)-6.10%

P/E Excl Extra (TTM)25.81x

LT Debt / Equity (Quarterly)0.24x

EPS Basic Excl Extra (TTM)$-0.06

P/TBV (Quarterly)2.06x

P/B Ratio (Annual)2.06x

Inventory Turnover (TTM)2.14x

Pretax Margin (TTM)-1.75%

Book Value / Share (Annual)$2.99

Price vs S&P 500 (13W)46.59%

Beta0.54x

P/FCF (Annual)75.63x

Revenue / Share (TTM)$3.31

ROE (TTM)-1.88%

52-Week Low$4.52

vGradeC

gGradeB

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q1 260.21est. —

Analyst Recommendations

Sep 2021

Oct 2021

Nov 2021

Dec 2021

4.14

Industry Peers — In Vitro Diagnostics(18)

Symbol	Value Score	Growth Score	Momentum Score	Price
ICCCImmucell Corp	C	B	B	$9.67
IDXXIdexx Laboratories Inc	D	B	C	$566.79
LNTHLantheus Holdings, Inc	C	B	B	$97.13
NNNNAnbio Biotechnology Class A Ordinary Shares	F	B	A	$30.17
CLDXCelldex Therapeutics, Inc	F	F	B	$30.14
NTLAIntellia Therapeutics, Inc	D	C	B	$13.73
NEOGNeogen Corp	C	C	C	$8.92
QDELQuidelOrtho Corporation Common Stock	B	C	D	$13.27
ACHVAchieve Life Sciences, Inc.	F	F	B	$5.30
MYGNMyriad Genetics Inc	C	C	D	$4.28
TKNOAlpha Teknova, Inc. Common Stock	C	C	B	$5.37

About

ImmuCell Corp develops and commercializes health products for the dairy and beef cattle industries. The company operates two business segments: Scours (First Defense, a USDA-regulated product to prevent disease in newborn calves) and Mastitis (Re-Tain, an FDA-regulated treatment for subclinical mastitis in dairy cows). The Scours segment generates the majority of company revenue.